Seek Labs (Salt Lake City, UT) joins ARPA-H’s Investor Catalyst Hub and BARDA’s RRPV, bringing CRISPR therapeutics, AI pathogen mapping, and molecular diagnostics to accelerate biomedical innovation and pandemic preparedness.
Salt Lake City, Utah – September 24, 2025
Seek Labs, a Salt Lake City–based biotech developing CRISPR therapeutics, AI-driven pathogen mapping, and equipment-free molecular diagnostics, has joined two federally supported innovation networks: the ARPA-H Investor Catalyst Hub and the BARDA Rapid Response Partnership Vehicle (RRPV).
The ARPA-H Investor Catalyst Hub, managed by VentureWell, a nonprofit organization that cultivates a pipeline of inventors, innovators, and entrepreneurs driven to solve the world’s biggest challenges. VentureWell supports early-stage science and technology innovators through funding, training, and access to networks and resources. As a spoke in the network, Seek Labs gains access to potential funding, flexible contracting, and opportunities to contribute to ARPA-H challenge areas. As a spoke in the network, Seek Labs gains access to potential funding, flexible contracting, and opportunities to contribute to ARPA-H challenge areas.
The BARDA RRPV supports rapid development of medical countermeasures for pandemics and other high-consequence biological threats. Membership allows Seek Labs to compete for project opportunities and collaborate with technologists, contractors, academia, and nonprofits in the network.
“Joining these networks reflects our commitment to advancing innovative solutions and strengthening national preparedness,” said Kim Wirthlin, Chief Strategy and Policy Officer at Seek Labs. “These memberships give Seek Labs the opportunity to contribute our technologies to accelerate biomedical innovation and deliver rapid, scalable responses to emerging health threats,” Wirthlin added.
Seek Labs develops full-stack health solutions, combining BioSeeker™, its intelligence layer mapping viral vulnerabilities, with PTAP™ programmable therapeutics and SeekIt™ molecular diagnostics, aiming to accelerate responses to emerging health threats.
To learn more, visit seeklabs.com.